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REVIEW
Pre-exposure prophylaxis (PrEP) in an 
era of stalled HIV prevention: Can it change the 
game?
Robyn Eakle1,2* , Francois Venter1 and Helen Rees1
Abstract 
Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years where clinical trials have 
now demonstrated the efficacy of oral PrEP, and the field is scaling-up implementation. The WHO and UNAIDS have 
made PrEP implementation a priority for populations at highest risk, and several countries have developed guidelines 
and national plans accordingly, largely based on evidence generated by demonstration projects. PrEP presents the 
opportunity to change the face of HIV prevention by offering a new option for protection against HIV and disrupting 
current HIV prevention systems. Nevertheless, as with all new technologies, both practical and social requirements 
for implementation must be taken into account if there is to be sustained and widespread adoption, which will also 
apply to forthcoming prevention technologies. Defining and building success for PrEP within the scope of scale-up 
requires careful consideration. This review summarises where the PrEP field is today, lessons learned from the past, the 
philosophy and practicalities of how successful programming may be defined, and provides perspectives of costs and 
affordability. We argue that a successful PrEP programme is about effective intervention integration and ultimately 
keeping people HIV negative.
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Introduction
Pre-exposure prophylaxis (PrEP) for HIV prevention has 
evolved significantly since the early conceptualization of 
protection tested in animal models [1] following evidence 
of prevention using antiretrovirals for occupational and 
non-occupational post-exposure prophylaxis [2, 3]. Since 
then, clinical trials have demonstrated the efficacy of oral 
PrEP, with evidence from 18 studies showing that “PrEP 
significantly reduced the risk of HIV acquisition” [4]. 
However, the level of efficacy varied according to differ-
ences in adherence within and across the study popula-
tions, with MSM showing higher levels of efficacy than 
found in the women-only studies [4]. Adherence is a cen-
tral component for consideration of programme plan-
ning, budget, and PrEP effectiveness.
The primacy of a combined effort including early 
antiretroviral treatment (ART) for HIV-positive people, 
rendering them non-infectious, and efficient preven-
tion interventions for HIV-negative people including 
condom distribution, treatment of sexually transmitted 
infections (STIs), post-exposure prophylaxis, and oral 
PrEP, voluntary medical male circumcision (VMMC), 
as well as continued outreach and education program-
ming, is necessary if the goal of controlling the epidemic 
by 2030 is to be realized [5]. The World Health Organi-
zation (WHO) and UNAIDS have made PrEP implemen-
tation a priority for populations at “substantial risk” [6, 
7], and several countries have developed guidelines and 
national plans integrating PrEP into programming, with 
the United States, South Africa, and Kenya among the 
first with official government-supported guidance [8–12]. 
These guidelines have been developed based on evidence 
emerging from demonstration projects [13].
Developing relevant and successful PrEP interventions, 
as well as defining what success is for those programmes 
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is a challenge that the HIV prevention world is currently 
evaluating and debating. Since PrEP will not be a stan-
dalone intervention and rather integrated into existing 
programming and systems, measures of success should 
take into account combination prevention and program-
ming as a whole. In addition, data suggest that while men 
can achieve good protection with PrEP even if doses are 
missed, women need to take PrEP every day to achieve 
high levels of efficacy [14, 15]. Evaluating effectiveness 
in a female population is thus strongly influenced by 
adherence, making its performance in the field harder to 
predict.
Mathematical modelling has suggested that PrEP could 
be part of changing the HIV prevention game, with the 
potential to enhance conventional prevention efforts, 
depending on the ability of programmes to prioritise 
those at risk and manage costs [16–19]. There is a des-
perate need for improved prevention efforts, so under-
standing how to strategically focus PrEP interventions 
to achieve optimal outcomes and to reinvigorate pre-
vention programmes, is of critical importance. Coupled 
with strategic planning is the need for demand and sup-
port for the intervention. In the United Kingdom (UK), 
grass-roots advocacy and support largely from the men 
who have sex with men (MSM) community has pushed 
for expanded availability of PrEP beyond those able and 
willing to pay out of their own pockets [20]. In Swaziland, 
a national pilot is underway to capitalize the success of 
the implementation of test and treat for HIV-positive 
people by adding PrEP as an option for those at higher 
risk of HIV in the general community [21]. These are 
just two separate examples of where ground up and top 
down support have pushed the availability of PrEP into 
a position to make a difference as a prevention system 
disrupter.
This review summarises the literature on where the 
PrEP field is today, discusses lessons learned thus far 
from intervention and service delivery integration sali-
ent to the introduction of PrEP, discusses the philosophy 
and practicalities of how successful PrEP programming 
may be defined, explores how the newness of PrEP may 
be leveraged as a system disrupter to encourage demand, 
and provides perspectives of prevention costs and cost 
effectiveness. We argue that developing and measuring a 
successful PrEP programme is about effective prevention 
intervention integration aimed at keeping people HIV 
negative.
PrEP: Where are we now?
Oral PrEP is now included as part of the recommended 
standard of prevention by the World Health Organiza-
tion (WHO) for people defined as being at “substantial 
risk” of HIV infection [6]. Substantial risk was defined 
in the 2016 Consolidated Guidelines on the Use of 
Antiretroviral drugs for Treating and Preventing HIV 
as geographical incidence of 3% or higher. However, the 
recommendation also suggests that 2% is sufficient, and 
considerations of population context, as well as demand 
should be taken into account, thereby effectively allow-
ing countries to interpret this definition as it is relevant 
to their particular settings. Oral PrEP has been registered 
for use by sexually active men and women, by several 
national drug regulatory authorities including the United 
States Food and Drug Administration (US FDA) and the 
South African Medicines Control Council (MCC). Imple-
mentation studies for different target populations have 
been completed or are in various stages across the globe 
[13].
The current oral PrEP strategy itself requires a daily 
commitment to pill taking, in particular for heterosexual 
women who appear to require higher concentrations of 
antiretrovirals in the genital tract to confer protection 
[14]. This is supported by preliminary evidence which 
suggests that in order to reach adequate drug levels in 
tissues exposed to potential HIV infection (e.g. vaginal 
and/or anal), women require near perfect adherence to a 
seven day regimen, where MSM may reach adequate lev-
els in anal tissues with only 4 days of pill taking in a week 
which can be non consecutive [14, 15]. Because of the 
significant behaviour requirements to maintain consist-
ent daily pill taking, additional options for PrEP delivery, 
including long-acting injectables, vaginal rings and films, 
are being developed to increase the selection of PrEP 
products and allow people to make choices about which 
technology best fits their lifestyles [22–24]. This scope 
of development is comparable to contraception where 
increasing the number of contraceptive options has been 
shown to significantly increase the overall uptake of con-
traception [25]. This seems to also be the case with the 
female condom where expanding the choice of product 
has improved access and use [26]. A vaginal ring contain-
ing the HIV drug dapivirine was recently tested in clinical 
trials and showed modest efficacy in preventing HIV, and 
an open label trial is now ongoing [27, 28]. Other prod-
ucts are in development, and it may take a few years to 
complete clinical efficacy studies, secure licensure and 
assess needs for implementation and cost [29]. In the 
meantime, noting the persistently high HIV incidence 
particularly among adolescent girls and young women 
(AGYW), and other vulnerable populations, it is critical 
to rollout oral PrEP as an expansion of prevention tech-
nology options and learn from the experiences of scaling 
it up which can later ease the way for new products.
Figure 1 shows a timeline for the last 20 years of ARV-
based prevention development and demonstrates the 
rapid increase in development activities over the last 
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10 years compared with the previous decade. This time-
line depicts the ‘scale-up’ in knowledge which happened 
over a period of time, gaining momentum with the 
results of each product. Although not all of the products 
or stepping stones illustrated here are of equal impact, 
each step in the development process contributed to the 
evolution of thinking and decisions in the development 
of ARV-based prevention technologies. Now, as the oral 
PrEP intervention is scaled-up in countries and new 
products come online, a similar escalation in learning 
from and accelerating implementation will ideally occur. 
Additional graphics and details of development can be 
accessed on the AVAC website [30].
 Per recommendations from mathematical model-
ling studies [16, 18, 35] as well as the WHO [36], first 
wave implementation studies have focused on delivering 
PrEP to populations at higher risk of HIV, in particular 
MSM and sex workers, as well as people who use drugs 
(PWUD) and AGYW to a lesser extent. This approach 
was aimed at optimising impact and cost effectiveness. In 
practice, these projects have mostly focused on MSM and 
sex workers where programmes have already been estab-
lished as a sort of “low hanging fruit” [13]. Beyond these 
first waves in defined programmes, however, identifying 
those at highest risk and prioritising risk groups brings 
significant challenges. Most populations at highest risk 
experience structural vulnerabilities such as lack of 
access to services, lack of information and/or criminali-
zation making them harder to reach [37]. Others have 
pursued studies for the harder to reach such as such as 
the SAPPH-IRe trial in Zimbabwe which combined pro-
vision of PrEP and test and treat through mobile clinics 
in rural areas throughout the country [38]. Second wave 
projects have been focusing on AGYW, which, while 
comprising only 11% of the population, are estimated to 
make up 20% of new HIV infections globally and are in 
great need of additional HIV prevention options [7, 39]. 
However, beyond sexual and reproductive health ser-
vices, to varying degrees depending on settings, AGYW 
are more difficult to engage in care or interventions 
such as PrEP because they are not necessarily grouping 
together in particular clinics or geographical/contextual 
areas (as opposed to MSM or sex workers) and therefore 
require a whole different approach to communication, 
education, and support for PrEP use.
From the few results reported thus far from demon-
stration projects, it appears that people at high risk are 
self-identifying and taking up PrEP [40, 41], but it may 
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Fig. 1 An illustration of the last 20 year of ARV-based prevention product development. Events above the timeline are related to the ARV-based 
prevention product pipeline and those below the line denote important milestones related to HIV prevention and care over the past 20 years. Dates 
and products represent timing of results unless otherwise noted. Data for this timeline were extracted from several sources [30–34]
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be that these people represent “early adopters” as the 
numbers are relatively small. These early adopters sit at 
the front of the bell curve that represents the Diffusion 
of Innovations theory [42]. This theory states that uptake 
of any new technology or behaviour starts with a small 
proportion of people adopting and promoting it to their 
communities. Perhaps one of the greatest challenges in 
PrEP delivery will be to engage the next level of adop-
ters who are at high risk, but may not initially be highly 
motivated to take it up. Promoting uptake, or generat-
ing demand in more sceptical communities, may involve 
a combination of strategies including social marketing 
and creative adherence support driven by lessons learned 
from outside the public health arena such as behavioural 
economics [43, 44]. Approaches will also have to be tai-
lored according to each population and geography. In this 
regard, viewing PrEP itself as a system “disrupter”, where 
the newness and promise of the product is a motivator in 
and of itself, will both require new strategies to engage 
PrEP-sceptical potential end-users as well as those who 
may have become impervious to prevention messaging 
and disinterested in available technologies. This element 
of capitalizing on the introduction of a new prevention 
option could be an important component of generating 
demand among the next set of adopters.
New prevention interventions: integration, 
programming, and lessons learned
The implementation of oral PrEP comprises a few critical 
logistical components. These include initial HIV testing 
to confirm an HIV-negative status, continued testing to 
ensure no change in HIV status, and monitoring of kid-
ney health. These are the basic clinical requirements as 
recommended in several guidelines [6, 8, 11, 12]. Addi-
tionally, these guidelines highlight the need to moni-
tor for potential hepatitis B infection, which does not 
exclude but could complicate PrEP use, other potential 
co-infections, and especially women who may be preg-
nant or breastfeeding where guidance on PrEP use is 
mixed. These components as currently stipulated require 
informed healthcare providers who can support their 
clients with information when they are making the deci-
sion as to whether to start PrEP, as well as support them 
during their time using PrEP with tailored adherence 
strategies.
With these requirements in mind, it is clear that new 
prevention technologies or interventions may be chal-
lenging to integrate into existing services if the specific 
requirements of introduction are different from what 
exists in the established system. Male condoms are the 
commonest and most successful prevention technology 
so far introduced. Overall they are inexpensive and widely 
utilised [45, 46], however, no intervention is perfect and 
male condoms have suffered from challenges like any 
other. Programmatic challenges have included issues with 
reliable distribution and access, as well as negative social 
connotations around trust and sex, and some reported 
problems with breakage [47–53]. Female condom pro-
grammes have been more challenging to introduce and 
sustain because of higher unit costs, limited distribu-
tion outlets, negative health care worker attitudes, and 
user acceptability [54, 55]. Similar challenges should be 
anticipated in the introduction of oral PrEP programme, 
as many female condom programmes floundered because 
of these obstacles. As with male and female condoms, 
consideration of where PrEP can and should be delivered 
will be critical so as not to limit access or stigmatise the 
product. Potential outlets could be specialised key popu-
lation clinics, general public health clinics, school health 
programmes, and sexual and reproductive health clinics, 
as well as mobile versions of all of these.
Another example is VMMC, a relatively simple, one-
time surgical, typically outpatient procedure, and once 
done offers lifelong partial protection against HIV. 
However, it took time to build VMMC into a viable ser-
vice from both the provider and the client perspectives. 
From the service delivery side, factors including “coun-
try ownership; sustained political will; service delivery 
efficiencies, such as task shifting and task sharing; use of 
outreach and mobile services; disposable, pre-packaged 
VMMC kits; external funding; and a standardized set of 
indicators for VMMC” were found to be the ingredients 
required for successful implementation and scale-up, 
while continual failures in supply chain management and 
unreliable funding sources caused issues in maintaining 
consistent service provision [56]. PrEP will need some of 
these same components to be successfully implemented 
and scaled-up, and in addition will have challenges such 
as repeat HIV testing, blood draws, and regular client fol-
low up. These ingredients for implementation speak to 
the required ownership, accountability, and pragmatism 
of integrating a new prevention intervention into systems 
already burdened with heavy patient volumes and logisti-
cal management issues.
Implementation of VMMC taught important lessons 
which could also inform PrEP rollout. Issues such as task 
shifting, the need for specific, easy to use kits for VMMC 
and the negative response of some men to compulsory 
HIV testing, had not been anticipated as challenges [57]. 
To address these issues, more resources were needed to 
develop strong community-based social marketing cam-
paigns as well as mechanisms to support men. Resources 
were aimed at messaging for men and women to promote 
the intervention, and in some cases, providing cancer 
screening services for women to promote a holistic health 
programme [58]. The observation that adjustments to the 
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VMMC programmes were required once implementa-
tion had begun, demonstrates the importance of continu-
ous, iterative programme review once a new technology 
is introduced. As with VMMC, developing supportive 
partner services, or options for partner engagement, 
could strengthen overall PrEP services and help to miti-
gate stigma and rumours arising from misunderstanding 
of the intervention.
Additionally, for PrEP to become normalized as an 
intervention, communities will need to become familiar 
and accepting of the concept. This will be challenging if 
only certain key populations are prioritised for rollout 
[59]. Messaging around the intervention will need to con-
sider social aspects of delivery which were also barriers 
in VMMC implementation. These include the potential 
for loss of income when at the clinic, fear of the proce-
dure or of side effects in the case of PrEP, lack of HIV risk 
perception, and lack of partner support [60–62].
Finally, and perhaps most unique to PrEP, is that it will 
be aimed at maintaining an HIV negative status in those 
at risk for HIV and will be used during periods of high 
risk rather than for a person’s entire life. The social and 
risk element is especially complex with the potential dif-
ficulties of identifying the high-risk groups, maintain-
ing engagement with them while mitigating stigma (and 
criminalization for some marginalised groups), provid-
ing tailored services that are acceptable, and having the 
individuals who are identified as being at risk, self-assess 
sufficiently to ensure adequate adherence. Getting these 
pieces right will also depend on how the larger commu-
nity understands the product (e.g. not as a “sex worker or 
MSM product”), and accepts and supports its implemen-
tation. The use of PrEP for limited portions of time will 
also add to the complexity of maintaining use during the 
time of need in these high-risk populations and convey-
ing appropriate messaging to that extent.
The focus on adherence
Like oral contraception, PrEP is a highly effective preven-
tion technology if taken consistently, notwithstanding 
the different efficacy requirements for women and men 
mentioned above. Adherence to PrEP is therefore key 
to the method’s success, yet there have been many chal-
lenges in ensuring adherence in clinical trials. Adher-
ence to PrEP (or lack thereof ) was why parts of one study 
[63], and another entire study [64] were not able to ade-
quately measure efficacy among women, where at least 
70% of participants in the VOICE trial and 60% in FEM-
PrEP did not use PrEP properly. The qualitative research 
published following the VOICE [65] and FEMPrEP [66] 
studies revealed highly nuanced reasons for lack of use, 
including misconceptions about personal risk, logistical 
issues attending the clinic, apathy towards research, and 
general lack of interest in the product but intense inter-
est in the high quality health services provided by the 
clinical trial clinics [65, 66]. This presented a challenge in 
the trials where women would tell clinical staff that they 
were adhering to their assigned regimens in order to keep 
coming to the clinic. Some observers questioned whether 
oral PrEP would ever be a viable product for women who, 
in large numbers in these studies, demonstrated little 
interest in consistent PrEP use. However it was generally 
agreed that in the absence of many prevention choices, 
that the product should be made available following addi-
tional research into the nuanced feedback received from 
the trials and previous prevention efforts [43, 67–70].
These insights are important as they point towards a 
need to conceptualize oral PrEP differently from other 
prevention methods and from the provision of ART, 
as well as build PrEP interventions into care valued by 
the community. Importantly, the duration of use will be 
determined by the needs of the individual. Taking PrEP 
over a period of time has been likened to “seasons of risk”, 
where someone may choose to take PrEP for a time, and 
then switch to another method [43, 71], as happens with 
contraception. As with contraception, as long as this 
engagement with products results in the desired outcome 
(maintaining a negative HIV status), then the program-
ming will be successful—e.g. PrEP does not have to be 
implemented in place of or to the detriment of male and 
female condoms, or other prevention strategies.
The provision of ART, especially as it expands into 
test and treat programming worldwide, has focused on 
uptake and consistent use of HIV treatment for life. This 
cannot be the mind set for PrEP, which must be delivered 
by providers with a message of flexibility thus promot-
ing honest feedback from clients who will need to engage 
with the best product available to stay negative. Pre-
senting PrEP to health care workers as being analogous 
to contraception is likely to be better understood rather 
than locating PrEP alongside HIV treatment. In addition, 
the early experiences of ART and its side effects persist in 
the memories of communities, which could be off putting 
for clients considering PrEP. With these issues in mind, 
supportive adherence counselling will be imperative for 
PrEP success [72].
Defining and building success
The primary measure of success for any HIV preven-
tion technology is the number of HIV infections averted 
over a period of time and in a prescribed population. 
However, this retrospective analysis can take a sig-
nificant effort and time to produce. To more accurately 
assess progress in shorter periods of time (quarterly or 
even annually), measurement of success is often limited 
to programmatic counting. For instance, the number of 
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condoms distributed to a given population in a given year 
is usually taken as whether a condom campaign has been 
successful. This metric, however, does not shed light as to 
whether people used the condoms.
Overall, for evaluating PrEP success, numbers of HIV 
infections averted will need to be modelled based on a 
range of composite programmatic measures. One impor-
tant metric will be uptake among those eligible for PrEP. 
However, eligibility will have to be well-defined and is 
currently different in some countries. There is clini-
cal eligibility of being HIV-negative with healthy kidney 
function which is universal in guidelines, however the 
question of risk is where countries currently differ. Kenya 
is prioritising people at higher risk in certain geographi-
cal areas [73], while South Africa is focusing only on key 
populations and has excluded pregnant and breastfeed-
ing women for the time being [10, 12]. Therefore, any 
comparisons of uptake across countries will need to keep 
these differences in mind. In addition, the denominator 
for who is actually eligible may be difficult to calculate 
depending on the validity of population demographics in 
a given setting.
Measuring uptake should also go a step further in 
determining the number of people newly engaging in or 
returning to care because of interest in PrEP. Since PrEP 
may actually act as a catalyst to reignite interest in HIV 
prevention services overall then accounting for increases 
in numbers of people coming to the clinic because 
of PrEP, whether they end up using it or not, is also an 
important measure of success for the larger prevention 
goal of staying HIV-negative. This will depend, however, 
on programmes having reliable data from before PrEP is 
introduced to be able to assess increases in numbers, as 
well as ideally recording in a standardized manner the 
purpose for engagement in care as well as date of previ-
ous HIV test and/or visit. In addition, it will be important 
to then analyse who is coming to the clinic in terms of 
(on a basic level) age, sexual behaviour, and gender.
Retention is a critical metric, but is also not so straight 
forward as there is the question of whether it is reten-
tion with use of PrEP, or rather maintaining consistent 
retention in care. Arguably, the latter could pose a better 
metric provided individuals remain HIV-negative given 
that is the primary purpose of PrEP and engagement in 
prevention services in the larger picture. Potentially both 
should be included, but in either case, the number of 
people returning for services will be important to cap-
ture. This brings a whole host of issues around how to 
track health service clients which are being tackled and 
tested through multiple creative efforts such as health 
cards, biometrics, and/or national electronic databases. 
The retention aspect should also take into account the 
notion that some people may fall out of PrEP use and so 
should be able to track whether they maintain consistent 
engagement with the system while they are in periods of 
lesser HIV risk [72, 74].
For the metric of retention including PrEP, there has 
been evidence to show that recording repeat refills can 
be useful as a composite measure for use and one that is 
far more sustainably collected as compared with MEMS 
or pill counting [72]. As with condoms, just counting the 
number of people taking up PrEP or pills distributed will 
not account for whether people actually used the prod-
uct. Adherence was a common metric in the PrEP effi-
cacy studies, but the measurement required drug level 
analyses, pill counting and some more advanced technol-
ogies such as medical event monitoring systems (MEMS) 
on pill bottles to electronically record when bottles are 
opened. These strategies were also used to determine 
how reliable participants’ self-reports were. Adherence 
measured in these relatively sophisticated fashions is not 
likely to be sustainable in a real-world environment due 
to labour burden, facility and budget capacities. In addi-
tion, measurement of adherence needs to be nuanced 
considering the cycles of risk, and differing levels of effi-
cacy between men and women.
Seroconversions to HIV-positive status can also be 
tracked to assess programme success in promoting and 
supporting PrEP use, or at the very least, success in 
engaging people in effective HIV prevention. Addition-
ally, if PrEP cycling is not managed well, there will be a 
risk for generating ARV resistance, although the PrEP 
efficacy and implementation studies, as well as pharma-
covigiliance research to date have shown the probability 
of resistance generated by PrEP to be very low [4, 75].
These indicators will inherently depend, however, on 
ongoing successful personal and provider assessment of 
risk which also does not negatively stigmatize those at 
higher risk. Many pilot studies are investigating the use 
of risk assessment tools with varying degrees of depth. 
Results over the coming months from these studies will 
provide insight as to whether these tools have been useful 
and to what degree they should be used in scale-up.
Finally, for there to be PrEP interventions to assess, 
there must be a market and therefore demand and sup-
port for them. Testing implementation in the field and 
paths to guidelines in the few countries which have 
already taken it on board have varied greatly according to 
context. In the UK, the PROUD study definitively demon-
strated the HIV protection potential of PrEP even before 
the end of the trial [76] and sparked grassroots demand 
from the MSM population for it to be offered through 
the National Health System (NHS). Negotiations are still 
ongoing due to the cost of integrating the drug into the 
NHS, however analyses have shown that existing PrEP 
provision through private clinics has likely contributed to 
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the significant decrease in new infections in the UK [20, 
77], further motivating continuous calls for PrEP avail-
ability. In Swaziland, where the test and treat strategy 
for ART was taken on board and had significant effects 
on reduction of community viral load, the government 
seized the opportunity to adopt PrEP through a national 
pilot in order to test the most effective way to utilize this 
new tool to further drive down the epidemic [21, 78]. 
These are two examples of how PrEP is making its way 
into systems from the bottom up and top down, where 
people have seen a need and seek to implement PrEP in a 
strategic way. This support is instrumental in paving the 
way for successful programming.
Cost‑effectiveness and affordability
Since before the clinical trials reported results of PrEP 
efficacy, there were significant modelling efforts to esti-
mate impact and cost-effectiveness of PrEP [79–81]. 
These studies relied heavily on estimated service costs as 
well as cost of the PrEP drugs themselves as there were 
no practical data from implementation. Since then, com-
modity costs have evolved, with tiered pricing which 
allow low and middle income countries to pay less for 
drugs than richer countries. The markets are now with 
opening further the availability of generic options [82].
Models have also evolved, updated and informed by 
efficacy estimates and service delivery costing demon-
strated in rollout studies [41, 83]. Cost-effectiveness, 
however, will depend on the ability of programmes to effi-
ciently integrate PrEP into existing services, and generate 
demand appropriately and relevantly among people at 
highest risk to take it up. To add to the complexity, it will 
also be important to consider whether PrEP become less 
cost-effective over time due to saturation and decreasing 
burden of new HIV infections necessitating the addition 
or increase of scale of other interventions.
In light of these complexities, an on-going challenge for 
many countries is how to incorporate PrEP into national 
plans with tight budget already allocated to existing ser-
vices, such as South Africa where PrEP is being consid-
ered within the context of an ever-growing national health 
budget and one of the largest ART programmes in the 
world [83]. In Kenya, a framework for PrEP implementa-
tion was developed highlighting a projected 5-year cost 
for PrEP sitting at just over at $328 million, and a funding 
gap of about $314 million. This is based on mathemati-
cal modelling of sub-county incidence rates with popula-
tion estimates aiming to geographically prioritize those 
at highest risk. The majority of the budget is devoted to 
commodity costs, knowing that the intervention is being 
integrated into existing services. With time, these services 
should adjust to make PrEP delivery more efficient and 
leverage the cyclical nature of individual PrEP use.
For now, no global funding programmes are providing 
country-level support specifically for PrEP. The United 
States Agency for International Development (USAID) 
provides some funding for PrEP through special large 
programme grants with specific aims. As yet, the Global 
Fund has only recently included PrEP in its country in 
its 2017–2022 strategy, but as stated it will be for select 
countries and it is not clear yet when this will be effected. 
For now, countries are making due with leveraging any-
thing available in their existing budgets as well as special 
programming to get PrEP provision off the ground.
In the meantime, the recent FDA approval [82], as well 
as approvals in other countries such as India and South 
Africa, of generic PrEP drugs should help to promote 
the availability of lower cost drugs especially in develop-
ing country settings. Additionally, the Medicines Patent 
Pool, an United Nations initiative launched in 2010 with 
a public health business model aimed at lowering prices 
for essential medicines, has played an important role in 
the license for the PrEP combination of TDF/FTC [84]. 
Following an update in 2017, the MPP license for PrEP 
now includes 116 countries. These efforts should help to 
alleviate pressure on many national budgets, as well as 
expand PrEP markets where it is currently not included 
in national health plans. The HIV epidemic in develop-
ing countries, and in particular sub-Saharan Africa, are 
in great need of new options such as PrEP and reduction 
in commodity costs is imperative to making new options 
available a reality. Additionally, there are also people in 
developed countries who do not have access to PrEP 
and want it, such as in the UK, Canada, and much of 
Europe [85, 86]. In 2015, the average cost of brand name 
Truvada-based PrEP in the United States was $1700 
per month [87], and has been reported to be between 
500 and 850 euros per month in Europe [88], thus plac-
ing high hopes on lowering costs and promoting better 
uptake among key populations. Advocacy to push for 
reducing the cost of PrEP to be offered through national 
health plans or insurance will be key to increasing avail-
ability in both developing and developed settings.
Conclusions
Oral PrEP is an effective HIV prevention intervention 
when taken consistently, and should be made easily avail-
able to those at high risk of HIV who are self-aware and 
able to make the commitment to be sufficiently adherent. 
Oral PrEP can pave the way for these new technologies, 
and the lessons learned in its implementation can be used 
to build stronger, more adaptable programmes. PrEP will 
not change the game on its own, but as a component 
of HIV programming has the ability to disrupt current 
systems and reinvigorate the HIV prevention field. The 
measurement of PrEP success should be reflected in the 
Page 8 of 10Eakle et al. Retrovirology  (2018) 15:29 
numbers of people coming for prevention services that 
include targeted PrEP, and ultimately in demonstrated 
reductions in new HIV infections. Nevertheless, as with 
all new technologies, there needs to be a social shift at 
a population level if there is to be sustained and wide-
spread adoption, which will also apply to prevention 
technologies in the development pipeline.
 What is the cost of not implementing PrEP, or other 
new prevention options? Research has shown that ART 
will not reduce the epidemic enough to move towards 
elimination, or even control [5]. For many populations, 
the reliance on old prevention interventions means that 
the risk of acquiring HIV remains unacceptably high 
[89]. If the goal of PrEP and other prevention program-
ming is to prevent new HIV infections, also reducing the 
escalating costs of ART as a lifelong public health inter-
vention, then offering PrEP in the spirit of promoting 
choice, accessibility, flexibility, and efficiency should be 
the first step in paving the way for new HIV prevention 
interventions.
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